Houlihan Financial Resource Group Ltd. Grows Position in Amgen Inc. $AMGN

Houlihan Financial Resource Group Ltd. boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 93.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,291 shares of the medical research company’s stock after purchasing an additional 1,594 shares during the quarter. Houlihan Financial Resource Group Ltd.’s holdings in Amgen were worth $1,102,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of AMGN. Anfield Capital Management LLC grew its holdings in Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares during the period. Dogwood Wealth Management LLC grew its holdings in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares during the period. Board of the Pension Protection Fund purchased a new stake in Amgen in the fourth quarter valued at approximately $26,000. Manning & Napier Advisors LLC raised its holdings in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after buying an additional 32 shares during the period. Finally, Olistico Wealth LLC purchased a new position in Amgen in the fourth quarter valued at approximately $33,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.85% of the company’s stock.

Amgen Trading Up 0.1%

NASDAQ AMGN opened at $336.48 on Friday. The company’s fifty day simple moving average is $342.83 and its 200-day simple moving average is $345.39. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The stock has a market cap of $181.60 billion, a P/E ratio of 23.42, a PEG ratio of 3.37 and a beta of 0.44.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same period in the previous year, the company posted $4.90 earnings per share. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts predict that Amgen Inc. will post 22.37 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is presently 70.15%.

Analyst Ratings Changes

Several research analysts recently commented on the stock. The Goldman Sachs Group raised their price target on shares of Amgen from $415.00 to $425.00 and gave the company a “buy” rating in a report on Friday, May 1st. Daiwa Securities Group cut their price target on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a report on Wednesday, May 13th. UBS Group raised their price target on shares of Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a report on Monday, April 13th. Erste Group Bank restated a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Finally, Citigroup raised their price target on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $355.19.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.